Abstracts Archive - Page 625 of 2607 - ACR Meeting Abstracts

Abstract Number: 2147 • ACR Convergence 2022
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
Filipe Pinheiro¹, Rui Gaspar², Bruno Fernandes³, Armando Peixoto², Guilherme Macedo² and Iva Brito⁴, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…
Abstract Number: 2149 • ACR Convergence 2022
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Francisca Guimarães¹, Maria Pontes-Ferreira¹, Catarina Soares¹, Hugo Parente², Carolina Ochôa Matos³, Roberto Costa³, Daniela Oliveira⁴, Catarina Abreu⁵, Rafaela teixeira⁶, Sofia Ferreira Azevedo⁷, João Madruga-Dias⁸, Filipe Araújo⁹, Carla Campinho Ferreira¹⁰, Daniela Santos-Faria² and José Tavares-Costa², ¹Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ²Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal, ⁵Rheumatology Department, Hospital Garcia de Orta, Lisboa, Portugal, ⁶Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ⁹Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ¹⁰Rheumatology Department, Hospital de Braga, Braga, Portugal
Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…
Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Iain B McInnes¹, Philipp Sewerin², Mohamed Sharaf³, Michela Efficace⁴, May Shawi⁵, Michelle Perate⁶, Miriam Zimmermann⁷ and Laura Coates⁸, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁴Janssen Cilag SpA, Imperia, Italy, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 2075 • ACR Convergence 2022
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
MI HYEON KIM¹, Eun Bong Lee¹, Eun Young Lee², Jin Kyun Park³ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University College of Medicine, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea
Background/Purpose: This study aimed to investigate the incidence and risk factors of bloodstream infection (BSI) in patients with systemic lupus erythematosus (SLE) receiving moderate-to-high dose…
Abstract Number: 2151 • ACR Convergence 2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Kurt de Vlam¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowinska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Frank Behrens¹², ¹University Hospitals Leuven, Leuven, Belgium, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement.…
Abstract Number: 1313 • ACR Convergence 2022
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
Laura Carbone¹, Petra Bůžková², John Robbins³, Howard Fink⁴, Joshua Barzilay⁵, Rachel Elam¹ and Carlos Isales¹, ¹Augusta University, Augusta, GA, ²University of Washington, Seattle, WA, ³UC Davis, Davis, CA, ⁴University of Minnesota, Minneapolis, MN, ⁵Kaiser Permanente, Atlanta, GA
Background/Purpose: Essential amino acids including tryptophan (trp) are building blocks for protein, and adequate protein intake is important for skeletal homeostasis. In experimental studies, trp…
Abstract Number: 1016 • ACR Convergence 2022
Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
Ivan Arias-de la Rosa¹, Elena Carnero-Montoro², lourdes Ladehesa-Pineda³, Clementina Lopez-Medina⁴, Rafaela Ortega-Castro¹, Maria del Carmen Abalos-Aguilera⁵, Daniel Dominguez-Toro⁶, Manuel Martinez-Bueno², Ruth Dominguez⁶, Olivia Castellini⁶, Guillermo Barturen², Chary López-Pedrera⁷, Eduardo Collantes¹, Marta Alarcon-Riquelme² and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁴Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁵Hospital Universitario Reina Sofia, Cordoba, Spain, ⁶GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors could be underestimating the subclinical atherosclerosis in patients with Spondyloarthritis (SpA). The identification of subclinical CVD sings and…
Abstract Number: 1020 • ACR Convergence 2022
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
Vartika Kesarwani¹, Stephanie Sinnappan², M. Elaine Husni³, Michael Weisman⁴ and Joerg Ermann⁵, ¹University of Connecticut, Farmington, CT, ²Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or…
Abstract Number: 1022 • ACR Convergence 2022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
Walter P Maksymowych¹, Anna Hadsbjerg², Mikkel Østergaard³, Raphael Micheroli⁴, Susanne J. Pedersen⁵, Adrian Ciurea⁶, Nora Vladimirova², Michael Nissen⁷, Kristyna Bubova⁸, Stephanie Wichuk⁹, Manouk de Hooge¹⁰, Ashish J Mathew¹¹, Karlo Pintaric¹², Monika gregova¹³, Ziga Snoj¹², Marie Wetterslev¹⁴, Karel Gorican¹⁵, Joel Paschke¹⁶, Iris Eshed¹⁷ and Robert G Lambert⁹, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁸First Faculty of Medicine, Charles University,, Prague, Czech Republic, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Ghent University Hospital, Luxembourg, Luxembourg, ¹¹Rigshospitalet, Copenhagen, Denmark, ¹²Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹³Institue of Rheumatology, Prague, ¹⁴Rigshospitalet, Copenhagen, Glostrup, Denmark, ¹⁵MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, ¹⁶CARE Arthritis LTD, Edmonton, AB, Canada, ¹⁷Sheba Medical Center, Tel Aviv, Israel
Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list…
Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Alexander Egeberg¹, William Tillett², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…
Abstract Number: 1023 • ACR Convergence 2022
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Isaac Cheng¹, Ying Ying Leung², Ho SO¹, Praveena Chiowchanwisawakit³, Stanley Angkodjojo⁴, Muhammad Saeed⁵, Kichul Shin⁶, Han Joo Baek⁷, Mohit Goyal⁸, Muhammad Haroon⁹, Eman Satti¹⁰, Nallasivan Subramanian¹¹, Fariz Yahya¹², Soosan Soroosh¹³, ASAL ADNAN RIDHA¹⁴, Ho Yin Chung¹⁵, James Cheng-Chung WEI¹⁶, Kishimoto Mitsumasa¹⁷ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ³Mahidol University, Bangkok, Thailand, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Central Park Medical College, Lahore, Pakistan, ⁶Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁷Gachon University College of Medicine, Inchon, Republic of Korea, ⁸CARE Pain & Arthritis Centre, Udaipur, India, ⁹Doctor, Tralee, Ireland, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Velammal Medical College Hospital, Velammal, India, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Army University for Medical School, Tehran, Iran, ¹⁴Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁵Chiron Medical, Hong Kong, Hong Kong, ¹⁶Chung Shan Medical University Hospital, Taichung, Taiwan, ¹⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…
Abstract Number: 1028 • ACR Convergence 2022
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
Conor Coyle¹, Caroline Whately-Smith², Melanie Brooke³, Uta Kiltz⁴, Ennio Lubrano⁵, Ruben Queiro⁶, David Trigos⁷, Jan Brandt-Juergens⁸, Salvatore D'Angelo⁹, Andrea Delle Sedie¹⁰, Emmanuelle Dernis¹¹, Philip Helliwell¹², Pauline Ho¹³, Axel Hueber¹⁴, BEATRIZ E. JOVEN¹⁵, Michaela Koehm¹⁶, Carlos Montilla¹⁷, Jon Packham¹⁸, JOSE PINTO TASENDE¹⁹, Felipe Julio Ramirez Garcia²⁰, Adeline Ruyssen-Witrand²¹, Rossana Scrivo²², sarah twigg²³, Martin Welcker²⁴, Theo Wirth²⁵, Laure Gossec²⁶ and Laura Coates²⁷, ¹Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ²Whately-Smith Ltd, Kings Langley, United Kingdom, ³Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oveido, Spain, ⁷Patient partner, Oveido, Spain, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹LE MANS general hospital, LE MANS, France, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹³The Kellgren Centre for Rheumatology, Manchester, United Kingdom, ¹⁴Paracelsus University Nürnberg, Erlangen, Germany, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ¹⁷Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁸University of Nottingham, Stafford, United Kingdom, ¹⁹SERGAS, A Coruña, Spain, ²⁰Hospital Clínic, Barcelona, Spain, ²¹CHU de Toulouse, Toulouse, France, ²²Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ²³Bradford Teaching hospitals NHS foundation trust, Bradford, United Kingdom, ²⁴GBR, Planegg, Germany, ²⁵Aix Marseille University, Marseille, France, ²⁶Sorbonne Université, Paris, France, ²⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous, multi-dimensional disease. Little is known about factors underpinning treatment intensification in routine practice. Treatment pathways are not well…
Abstract Number: 1031 • ACR Convergence 2022
Foot Involvement in Psoriatic Arthritis- a Retrospective Study
Sofia Ferreira Azevedo¹, Carolina Mazeda², Susana P. Silva³, Claudia P. Oliveira¹ and Anabela Barcelos³, ¹Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ²Centro Hospitalar Baixo Vouga, Ovar, Portugal, ³Centro Hospitalar Baixo Vouga, Aveiro, Portugal
Background/Purpose: Foot involvement is well recognized in many inflammatory rheumatic diseases, namely in Spondylarthritis (SpA), where its early recognition is of utmost importance. Psoriatic arthritis…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].